Inclusion Criteria:  Aged 18-80 years  Planned to receive conventional chemotherapy such as:  CMF (cyclophosphamide (Endoxan), methotrexate, 5-FU)) Standard AC+T regimen (doxorubicin (Adriamycin)), cyclophosphamide (Endoxan), Taxane [paclitaxel (Taxol) or docetaxel (Taxotere)) or any combination of two or more components (e.g., ACT, TAC, TA, AT, AC) ABVD (doxorubicin (Adriamycin), bleomycin, vinblastine, dacarbazine) FOLFIRI (irinotecan, 5-FU, leucovorin) Any other 5-FU-based regimen Planned to receive at conventional new generation targeted agents (tyrosine-kinase inhibitors or monoclonal antibodies) such as cetuximab, axitinib, bevacizumab, sunitinib, and sorafenib, temsirolimus, everolimus, vemurafenib, dabrafenib. Be willing and able to complete all study-related activities Properly obtained written informed consent  Exclusion Criteria:  Receiving any oxaliplatin-containing chemotherapy regimen, such as FOLFOX Concurrent radiotherapy Unable or unwilling to complete study assessments Concurrent participation in another interventional clinical study or use of another investigational agent within 30 days before randomization Any other clinical or psychiatric condition or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study or unable to comply with the protocol Chronic use of opioid analgesics